This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Edmund J. Lewis, MD
for the Collaborative Study Group Rush-Presbyterian-St Luke's Medical Center Chicago, Ill

JAMA. 1995;273(23):1831.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In a recent letter, Dr Sawicki and colleagues¹ question whether captopril has kidney-protecting properties and, therefore, whether it is superior to conventional antihypertensive treatment. In formulating their argument, the authors quote information that is not accurate with respect to our own publication.² For example, the rates of loss of creatinine clearance they attributed to patients in our study were much higher than those that we actually experienced. As we noted, we carried out a logarithmic transformation of sequential measurements of the creatinine clearances to improve the distributional assumptions of a simple, linear, random-effects model. We reported the rate of change as a percentage per year, rather than milliliters per minute per year. The placebo group diminished their creatinine clearance at a rate of 17% per year, as opposed to the captopril group, which lost function at 11% per year (P=.03). We believe that this . . . [Full Text PDF of this Article]

Footnotes
Edited by Drummond Rennie, MD, Deputy Editor (West), and Margaret A. Winker, MD, Senior Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?